Loading...
•
Sep 30, 2022
Pacific Biosciences Q3 2022 Earnings Report
Pacific Biosciences' Q3 2022 financial results were announced, with revenue growth driven by instrument sales and consumables.
Key Takeaways
Pacific Biosciences reported revenue of $33.8 million for Q3 2022, a 60% increase compared to Q3 2021. The company's results were driven by growth in instrument revenue and consumables revenue. The company provided a positive outlook for the rest of the year.
Revenue was $33.8 million, up 60% year-over-year.
Instrument revenue was $17.9 million, up 125% year-over-year.
Consumables revenue was $12.5 million, up 23% year-over-year.
Service and other revenue was $3.4 million, up 13% year-over-year.
Revenue by Segment
Forward Guidance
PacBio expects revenue to be in the range of $125 million to $135 million.
Positive Outlook
- PacBio expects revenue to be in the range of $125 million to $135 million.
- Continued growth in instrument sales.
- Increased demand for consumables.
- Growing installed base of Sequel II/IIe systems.
- Expanding applications of SMRT sequencing.
Challenges Ahead
- Potential for supply chain disruptions.
- Uncertainty in the macroeconomic environment.
- Competition from other sequencing technologies.
- Fluctuations in foreign currency exchange rates.
- Higher operating expenses.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...